Virtual ACC 2020 | TWILIGHT-COMPLEX: Ticagrelor Monotherapy in the Most “Dangerous” Angioplasties

The original TWILIGHT findings in more than 9000 patients who underwent angioplasty were presented last year at TCT and showed a 3.1% absolute risk reduction in BARC 2, 3, or 5 bleeding with no increase in death, infarction, or stroke in patients who received ticagrelor and placebo compared with patients who received ticagrelor and aspirin. All patients had previously received dual antiplatelet therapy for 3 months and had not experienced any bleeding or thrombotic events during that period of time.

Now, the TWILIGHT-COMPLEX trial is presented at the virtual ACC 2020 virtual while simultaneously published in J Am Coll Cardiol. This study focused on 2343 patients from the original TWILIGHT trial, who underwent complex angioplasty defined as: 3 vessels treated (9.1%), ≥3 lesions treated (29.9%), total stent length >60 mm (51.8%), bifurcation lesion with 2 stents implanted (10.7%); use of any atherectomy device (10.4%), left main disease (15.1%), venous or arterial bypass graft (6.9%), and chronic total occlusion (19%).

Compared with the main TWILIGHT population, these patients were older and more likely to have chronic kidney disease or anemia, and present acute coronary syndrome.

The primary endpoint of BARC 2, 3, or 5 bleeding was 4.2% in patients with complex angioplasty in the ticagrelor monotherapy group vs. 7.7% in patients in the dual antiplatelet therapy group (a similar reduction to that experienced by patients who underwent noncomplex angioplasty). A similar finding was observed for major (BARC 3 to 5) bleeding only.


Read also: Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves.


Just like in the general population, there were also no differences in death, infarction, or stroke between ticagrelor monotherapy and dual antiplatelet therapy, and the same happened with definite/probable thrombosis.

Original Title: Ticagrelor with aspirin or alone after complex PCI: the TWILIGHT-COMPLEX analysis.

Reference: Dangas G et al. J Am Coll Cardiol. 2020; Epub ahead of print y presentado en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

IVUS Optimized Left Main 2-Stent Strategy: Should We Drop the 5-6-7-8 Criterion?

Provisional stenting in bifurcations has shown better results at mid and long term vs initial two stent strategy, according to Bifurcation Club consensus. However,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....